Efficacy and Safety of NNC0109-0012 (Anti-IL-20 mAb) in Patients with RA: Results from a Phase 2a Trial

Summary

Elevated expression of interleukin-20 (IL-20) and its receptors has been demonstrated in synovium from patients with rheumatoid arthritis (RA) and is thought to be implicated in the pathogenesis of RA. NNC0109-0012 is a novel human monoclonal IgG4 antibody that binds to and neutralizes the activity of IL-20. Results of a Phase 2 study suggest that IL-20 is a potential target for RA therapy.

  • Rheumatology Clinical Trials
  • Rheumatoid Arthritis
View Full Text